presence of microhaematuria, systolic and diastolic blood pressure and proteinuria during follow-up were associated with an unfavourable outcome. By multivariate analysis, mean proteinuria during follow-up remained as the only significant risk factor (OR, 2.72; 95% CI, 1.59-4.64). Renal survival for patients with mean proteinuria <0.5 g/24 h was 100 and 95% after 5 and 10 years, respectively. The number of patients who improved or stabilized their renal function significantly increased in the second and third periods of the study .
Introduction
Malignant hypertension (MHT) is defined by very high blood pressures (BP) accompanied by bilateral haemorrhages or exudates, or both, with or without papilloedema in funduscopic examination. Although some studies reported a decrease in the incidence of MHT in recent decades [1] , other investigations have not confirmed this trend [2] [3] [4] , showing on the contrary a persistence in the number of cases, an estimated 1-2 new cases per 100 000 persons per year [4] .
Earlier clinical descriptions of MHT reported a dismal prognosis, with a very low patient survival [5] [6] [7] . The prognosis started to improve after 1970, with the development of modern antihypertensive drugs. Some series published in those years reported renal and patient survival of 50 and 75%, respectively, at 5 years [8] . The introduction of calcium channel blockers (CCB) and of drugs that block the renin-angiotensin system (RAS) after 1980 was followed by a further improvement of prognosis, with renal and patient survival of 81 and 90%, respectively, at 5 years [9] [10] [11] [12] [13] [14] .
Several clinical and analytical parameters at presentation have shown a significant prognostic influence. Among them, the degree of renal function and the value of proteinuria at presentation, Afro-American ethnicity and a secondary aetiology of MHT (in opposition to malignized essential hypertension) have confirmed this negative prognostic impact along several clinical studies [13, 15, 16] . Nevertheless, very few have investigated the influence of clinical and analytical variables throughout follow-up on the long-term outcome of MHT patients. This issue is particularly relevant considering that, nowadays, the majority of patients remain fortunately alive after the diagnosis and treatment of MHT; the identification of those factors that would influence the long-term outcome of renal function should be extremely important in order to avoid the need for chronic maintenance therapy.
The aims of the present retrospective study are to report the long-term outcome of renal function in a cohort of 197 patients with essential MHT in whom a longterm follow-up was performed and to identify those clinical and biochemical factors having an influence on the final results. In addition, we aimed to analyse possible differences and historical trends along the different periods of the study. The primary outcome was the improvement or stabilization of renal function after the diagnosis of MHT. Major secondary outcomes included the need for maintenance dialysis, cardiovascular events and all-cause mortality.
Materials and methods
This retrospective study was performed in a single centre, Hospital 12 de Octubre, Madrid, Spain. Hospital 12 de Octubre is a tertiary hospital attending a population that has oscillated between 650 000 and 900 000 persons since its foundation.
Patients
We performed a retrospective analysis of patients with essential MHT diagnosed in our hospital in the period September 1974-December 2007. The diagnosis of MHT was based on the detection of very high BP accompanied by a hypertensive retinopathy Grade III or IV.
We initially obtained a list of all of the patients who had been seen with a diagnosis of MHT at our hospital during the above referred period. The case records of all these patients were examined in order to assure that the diagnosis of MHT was correctly established, according to the diagnostic criteria referred above. Three hundred and twenty-nine patients met these criteria. All the cases (102 patients) in whom a diagnosis of secondary MHT was established were excluded from the study. Three patients died during the initial admission because of stroke (two patients) and uraemic complications (one patient). Twenty-seven patients did not perform any follow-up visit after hospital discharge, whereas regular follow-up after hospital discharge was available in the remaining 197. The date of hospital admission with the diagnosis of MHT was established as the baseline point for each patient. Mean follow-up was 93 ± 88 months.
Fifty-two patients (26%) were lost to follow-up after a mean follow-up of 60 ± 63 months. Their mean serum creatinine (Scr) and proteinuria in the last visit were 1.6 ± 1.2 mg/dL and 0.5 ± 1.2 g/24 h, respectively, without significant differences with respect to the remaining patients. Their data were censored at the last visit and included for the analysis.
Data collection
Demographic, clinical and analytical data were compiled from medical records. All the cardiovascular events (myocardial infarction, unstable angina, heart failure, atrial fibrillation and stroke) were recorded, independently of whether hospitalization was required or not.
Estimated glomerular filtration rate (eGFR) was calculated by the modification of diet renal disease-4 formula (MDRD-4) equation.
For each patient, an average systolic blood pressure (SBP) and diastolic blood pressure (DBP) was determined for each 6-month block during follow-up; the averages of every 6-month period SBP and DBP are represented by the time-averaged SBP and DBP. Proteinuria during follow-up was measured by 24-h urine protein collection. Although protein/creatinine ratio could have been a more reliable marker of proteinuria than 24-h proteinuria, it was impossible to retrospectively obtain the data required to calculate this ratio in patients diagnosed before 1990. In a similar manner to SBP and DBP, the time-averaged proteinuria represents an average of the mean of every 6-month period's proteinuria measurements.
Complete therapy was carefully recorded, both at admission and during follow-up. Oral antihypertensive drugs prescribed to every patient were grouped into the following classes: RAS blockers (angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers), CCB, beta blockers (BB) and diuretics. Patients were censored at the start of renal replacement therapy, death or lost to follow-up.
Outcome
The primary outcome of the study was the improvement or stabilization of renal function after the diagnosis of MHT. Major secondary outcomes included the need for maintenance dialysis, cardiovascular events and allcause mortality.
Definitions
The improvement or stabilization of renal function was defined by a Scr that did not increase >0.3 mg/dL during follow-up in patients with a baseline Scr <1.5 mg/dL, >0.5 mg/dL in those with a baseline Scr 1.5-2.5 mg/ dL and >0.7 mg/dL in patients with a baseline Scr >2.5 mg/dL. Patients were grouped according to the presence of improvement or stabilization of renal function during follow-up (Group 1) or renal function worsening (Group 2).
Renal impairment was defined by an eGFR lower than 60 mL/min/m 2 . Microhaematuria was defined by the presence of at least five erythrocytes per high power field in urinary sediment examination and proteinuria by a urinary protein excretion higher than 0.3 g/24 h.
In order to analyse if the incidence, clinical presentation and prognosis of essential MHT had changed over time, the whole period of the study 
Statistical analysis
Clinical characteristics at presentation and patient survival were analysed in the cohort of 227 patients diagnosed of essential MHT. Long-term outcome analyses were confined to the 197 patients in whom data about follow-up were available. Normally distributed variables are displayed as mean ± standard deviation or 95% confidence interval and compared using Student's t-test, Fisher's test, one-way analysis of variance or Pearson's correlation coefficients. Categorical variables are expressed as percentage and compared with chi-square test. The probability of survival with improved or stable renal function after initial admission, as well as survival without chronic dialysis and patient survival, was calculated by means of Kaplan-Meier analysis and curves were compared with the use of the log-rank test. Cox proportional hazard model was performed to explore the influence of several variables on the occurrence of survival. Only variables being significant in univariate analysis were included by forward stepwise entry into the multivariate model.
A P-value of <0.05 was considered significant. Statistical analysis was performed with the SPSS software (version 15.0 for Windows).
Results

Presentation
The most relevant clinical characteristics at baseline are shown in Table 1 . Almost all the patients were Caucasians (220 patients, 96.9%); 6 (2.6%) patients were Black and 1 (0.4%) was Oriental.
Treatment
All the patients were treated rapidly and aggressively to decrease BP to values lower than 140/90 mmHg. Oral antihypertensive drugs were started immediately after admission, RAS blockers (72%), diuretics (49%), CCB (38%) and BB (33%) being the most commonly prescribed agents. Patients continued to receive these oral antihypertensive agents after hospital discharge and most of them needed more than one class of antihypertensive drugs to control BP; the mean number of antihypertensive drugs prescribed during follow-up was 2.9 ± 1.1, ranging from 0 to 6.
Renal involvement
Renal function impairment was detected at admission in 144 patients (63%). Among them, 125 (85%) had an acute worsening of renal function. Fifteen patients (6.6%) required haemodialysis treatment shortly after their admission because of severe renal impairment and uraemic symptoms. Of them, seven (46.7%) had previous chronic renal impairment. Only two patients (13%) partially recovered the sufficient renal function to abandon dialysis.
Long-term renal function outcome
Long-term outcome of renal function was analysed in 197 out of the 227 patients in whom follow-up was available. In 149 patients (75.6%) (Group 1), renal function showed an improvement or stabilization during follow-up, whereas it deteriorated in the remaining 48 (24.3%) (Group 2). As it is shown in Table 1 , patients of Group 2 had a significantly worse renal function at baseline, higher proteinuria and a more common finding of microhaematuria than Group 1 patients.
The evolution of clinical parameters during follow-up is expressed in Table 2 . Group 1 patients showed a better control of BP and had a mean proteinuria significantly lower than those in Group 2. The number of Group 1 patients treated with RAS blockers, CCB and BB was higher than in Group 2, but this difference did not reach statistical significance.
As shown in Table 3 , the following factors were significantly associated with an increased risk of renal function worsening during follow-up by univariate analysis: diagnosis during the first period (1974-85); previous chronic kidney disease; baseline renal function (Scr and eGFR) and proteinuria; presence of microhaematuria; and SBP, DBP and proteinuria during follow-up. By multivariate analysis, only follow-up proteinuria (OR, 2.72; 95% CI, 1.59-4.64) maintained its significance as risk factor associated with such unfavourable prognosis. Univariate and multivariate analyses performed after the exclusion of those patients with known chronic kidney disease (n = 16) showed similar results: follow-up proteinuria (OR, 3.37; 95% CI, 1.78-6.38) was the only factor significantly associated with the risk of renal function worsening.
Patients were stratified according to the mean timeaveraged proteinuria during follow-up in four groups: proteinuria <0.5 g/24 h (n = 151), 0.5-1 g/24 h (n = 10), 1-2 g/24 h (n = 17) and >2 g/24 h (n = 19). As shown in Figure 1 , the probability of renal survival (estimated on the basis of an improvement or stabilization of Scr during follow-up) was significantly higher among those patients in whom proteinuria had been maintained below 0.5 g/ 24 h in comparison with patients with proteinuria higher than 0.5 g/24 h (P < 0.00001). Renal survival for patients with proteinuria <0.5 g/24 h was 100, 100, 95 and 85% after 1, 5, 10 and 20 years of follow-up, in comparison with 86, 50, 8 and 0% at the same periods of follow-up for patients with proteinuria >2 g/24 h.
Chronic dialysis
Of the 48 patients with progressive renal function worsening (Group 2), 40 (83.3%) finally needed maintenance dialysis. By multivariate analysis, only Scr at baseline (OR, 1.66; 95% CI, 1.05-2.62) and follow-up proteinuria (OR, 3.36; 95% CI, 1.75-6.45) showed a significant association with the risk of chronic dialysis. Renal survival without chronic dialysis for the whole group of patients was 90, 84, 77 and 68% after 1, 5, 10 and 20 years of follow-up, respectively.
Cardiovascular events and mortality
Forty-six cardiovascular events appeared during follow-up in 33 patients: 24 cerebrovascular events, 11 acute coronary syndromes, 5 episodes of heart failure and 6 severe peripheral arterial disturbances. Smoking and SBP at pre- Of the 227 patients with essential MHT, 9 (3.9%) died, 3 of them during the initial admission (stroke in 2, uraemic complications in 1) and 6 during follow-up. By KaplanMeier analysis, patient survival for the whole cohort of patients with essential MHT was 97, 96, 96 and 91% after 1, 5, 10 and 20 years of follow-up, respectively.
Incidence of MHT and changes over time
The incidence of new patients with essential MHT remained stable during the different periods of the study. As shown in Table 4 , BP values, the number of patients treated with diuretics and the number of patients who started chronic dialysis were significantly higher among those diagnosed in the first period of the study. On the contrary, the number of patients treated with RAS blockers and CCB and the number of those who improved or stabilized their renal function were significantly higher among those diagnosed in the second and third periods.
Discussion
Although some studies have reported a decreasing incidence of MHT in the last decades [1] , others have not confirmed this tendency [2] [3] [4] . Our study agrees with the latter, showing a stable incidence of MHT throughout the duration of the study .
Earlier reports depicted a very poor renal prognosis for MHT patients, with an important proportion of surviving patients needing chronic dialysis or transplantation. Our study confirms that renal involvement is a major component of essential MHT, with a majority (63%) of patients presenting with an acute derangement of renal function. However, renal prognosis of our patients exhibits a clearly Table 4 . Clinical features during the three periods of the study (1974-85, 1986-96 and 1997-2007 favourable change in comparison with classic series. Renal function improved or remained stable after diagnosis in the majority of our patients and the probability of renal survival for the whole cohort (estimated on the basis of an improvement or stabilization of Scr during follow-up) was 84 and 72% after 5 and 10 years of follow-up, respectively. Furthermore, a tendency to better results regarding renal prognosis was observed along the last periods of our study. With regard to long-term renal survival of MHT patients, previous studies underlined the prognostic value of renal impairment at presentation as well as the beneficial influence of a tight control of BP during follow-up [13, 15, 16] . Our study also confirms that the severity of renal failure at presentation and a worse BP control during follow-up are detrimental prognostic factors for renal survival. However, a new parameter, not analysed in previous studies, emerged in ours as the most important prognostic factor for renal survival: mean proteinuria during followup. In fact, multivariate analysis showed that mean proteinuria during follow-up was the only significant prognostic parameter for the improvement or stabilization of renal function after initial diagnosis.
The crucial role of follow-up proteinuria among our patients agrees with the important prognostic influence that residual proteinuria has been shown to play in several chronic renal diseases [17, 18] and it is particularly interesting with regard to the choice of antihypertensive agents [19] . Many experimental and clinical studies have demonstrated that RAS blockers share a specific anti-proteinuric effect and that the beneficial effect that these agents have shown in diabetic and non-diabetic nephropathies [17, 19, 20] are mainly related to a reduction in proteinuria. Our data strongly suggest that the treatment of MHT patients should be based on RAS blockers, in order to provide a reassuring low amount of proteinuria during follow-up in addition to a strict control of BP. The involvement of RAS exacerbation in the pathogenesis of MHT [21] would increase the indication of these agents in MHT patients. On the other hand, it is tempting to speculate that the improvement in the long-term prognosis of MHT could be related to the availability of RAS blockers in recent decades. Whereas only a few patients in the first study period (1974-85) were treated with RAS blockers, the majority of patients received these agents in the second (1986-96) and third (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) periods in which renal prognosis significantly improved.
Our study has several limitations, derived from its retrospective design. We cannot rule out the influence of confounding, non-identified factors on the long-term outcome of our cohort. Almost all the patients were Caucasians and, therefore, our results might not be applicable to patients with MHT from other races. On the other hand, the main strength of our study relies on the systematic follow-up of our patients and the disposal of their renal parameters throughout evolution.
Conclusion
In conclusion, patient and renal survival in MHT have improved in recent years and mean proteinuria during follow-up emerges as a very important prognostic factor for long-term renal outcomes. Taking into account that RAS activation is a key pathogenic mechanism in MHT and that RAS blockers have specific anti-proteinuric properties, treatment of MHT patients should be mainly based on this type of agents, with the addition of other antihypertensive agents, if required, to maintain a strict control of BP during follow-up.
